Presepsin in risk stratification of SARS-CoV-2 patients

Zaninotto, Martina; Mion, Monica; Cosma, Chiara; Rinaldi, Daniela; Plebani, Mario

doi:10.1016/j.cca.2020.04.020

Cited by 68 publications

(76 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have been published after our search dates which provide additional LoS estimates from outside of China. A study of 5700 patients from hospitals in the New York area reported comparable estimates for total LoS (median 4.5; IQR 2.4-8.1) [51]; however, studies from Northern Italy [52], Japan [53], and California and Washington [50] reported longer estimates of LoS. Therefore, the total LoS outside of China may in fact be longer than what we concluded.…”

Section: Limitations and Biasescontrasting

confidence: 41%

COVID-19 length of hospital stay: a systematic review and data synthesis

Rees

Nightingale

Jafari

et al. 2020

BMC Med

545

410

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has placed an unprecedented strain on health systems, with rapidly increasing demand for healthcare in hospitals and intensive care units (ICUs) worldwide. As the pandemic escalates, determining the resulting needs for healthcare resources (beds, staff, equipment) has become a key priority for many countries. Projecting future demand requires estimates of how long patients with COVID-19 need different levels of hospital care. Methods: We performed a systematic review of early evidence on length of stay (LoS) of patients with COVID-19 in hospital and in ICU. We subsequently developed a method to generate LoS distributions which combines summary statistics reported in multiple studies, accounting for differences in sample sizes. Applying this approach, we provide distributions for total hospital and ICU LoS from studies in China and elsewhere, for use by the community. Results: We identified 52 studies, the majority from China (46/52). Median hospital LoS ranged from 4 to 53 days within China, and 4 to 21 days outside of China, across 45 studies. ICU LoS was reported by eight studies-four each within and outside China-with median values ranging from 6 to 12 and 4 to 19 days, respectively. Our summary distributions have a median hospital LoS of 14 (IQR 10-19) days for China, compared with 5 (IQR 3-9) days outside of China. For ICU, the summary distributions are more similar (median (IQR) of 8 (5-13) days for China and 7 (4-11) days outside of China). There was a visible difference by discharge status, with patients who were discharged alive having longer LoS than those who died during their admission, but no trend associated with study date. Conclusion: Patients with COVID-19 in China appeared to remain in hospital for longer than elsewhere. This may be explained by differences in criteria for admission and discharge between countries, and different timing within the pandemic. In the absence of local data, the combined summary LoS distributions provided here can be used to model bed demands for contingency planning and then updated, with the novel method presented here, as more studies with aggregated statistics emerge outside China.

show abstract

Section: Limitations and Biasescontrasting

confidence: 41%

COVID-19 length of hospital stay: a systematic review and data synthesis

Rees

Nightingale

Jafari

et al. 2020

BMC Med

545

410

View full text Add to dashboard Cite

show abstract

“…Among all, lymphopenia, thrombocytopenia, leucocytosis, CRP, PCT, LDH, AST, ALT, D-dimer, cTn represent the most predictive parameters of severe COVID-19 [17,26]. In addition to traditional biochemical biomarkers, it would be interesting to assess the role of new promising biomarkers, such as presepsin and MDW, for the early identification of patients at increased risk of complications [62,63].…”

Section: Discussionmentioning

confidence: 99%

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

Ciaccio

Agnello

2020

Diagnosis

View full text Add to dashboard Cite

AbstractCoronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease, which can evolve into multi-organ failure (MOF), leading to death. Several biochemical alterations have been described in COVID-19 patients. To date, many biomarkers reflecting the main pathophysiological characteristics of the disease have been identified and associated with the risk of developing severe disease. Lymphopenia represents the hallmark of the disease, and it can be detected since the early stage of infection. Increased levels of several inflammatory biomarkers, including c-reactive protein, have been found in COVID-19 patients and associated with an increased risk of severe disease, which is characterised by the so-called “cytokine storm”. Also, the increase of cardiac and liver dysfunction biomarkers has been associated with poor outcome. In this review, we provide an overview of the main biochemical characteristics of COVID-19 and the associated biomarkers alterations.

show abstract

“…Many additional inflammatory biomarkers have been studied and associated with poor outcome in SARS-CoV-2 infection. Examples include interleukin-6 (IL-6), interferon gamma-induced protein 10, monocyte chemotactic protein-3 and presepsin [25][26][27]. However, given that such biomarkers cannot be easily assayed in all laboratories and that evidence is unclear as to whether they add any clinical value beyond that already obtained through measurement of more standard inflammatory markers, we would not currently recommend their routine measurement in the absence of further research on clinical utility.…”

Section: Markers Of Coagulopathymentioning

confidence: 99%

IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Thompson

Bohn

Mancini

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

show abstract

Presepsin in risk stratification of SARS-CoV-2 patients

Cited by 68 publications

References 13 publications

COVID-19 length of hospital stay: a systematic review and data synthesis

COVID-19 length of hospital stay: a systematic review and data synthesis

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Contact Info

Product

Resources

About